Alle Storys
Folgen
Keine Story von curasan AG mehr verpassen.

curasan AG

euro adhoc: curasan AG
other
curasan AG: New Products for Oral Surgery

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
New Products
12.03.2008
curasan AG (ISIN DE 000 549 453 8) listed in the Prime Standard 
signed a distributorship agreement with Osteogenics Biomedical Inc., 
Lubbock, Texas, USA.
Thereby, curasan is granted the distribution rights for a powerful 
product package expected to be marketed throughout Europe under 
curasan´s own brand name as of summer of 2008. The package contains, 
among others, five membrane lines with different features, available 
in various sizes and shapes, suitable for specific indications.
With this considerable product line extension in the field of dental 
surgery and implantology curasan provides known products of optimized
quality as well as new solutions which ideally supplement the 
existing range.
These products, the license for which was obtained without 
significant advance costs, will contribute substantially to the 
planned overproportional growth in sales.
About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an 
exchange-listed company, is a leading innovator within the growth 
market of bone and tissue regeneration. The company has developed a 
comprehensive product range centred around its synthetic bone 
regeneration material Cerasorb®, for use in soft and hard tissue. 
With the REVOIS® implant system, the company's sales is focusing more
prominently on the growth market of dental surgery/implantology. The 
majority of new products emerging from the substantial development 
pipeline are to be offered under licence within other medical fields.
Please visit curasan's corporate website at www.curasan.com
end of announcement                               euro adhoc

Further inquiry note:

Dr. Erwin Amashaufer, curasan AG, phone +49 6027 4686-465, email:
ir@curasan.de
Andrea Weidner, curasan AG, phone +49 6027 4686-467, email: pr@curasan.de

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade

Weitere Storys: curasan AG
Weitere Storys: curasan AG
  • 14.06.2007 – 14:33

    euro adhoc: curasan AG / Director's Dealings

    Notification concerning transactions by persons discharging managerial responsibilities pursuant to section 15a of the WpHG, transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement. 14.06.2007 Xetra (euro adhoc) - Details of the person subject to the disclosure requirement: Name: Hans Dieter Rössler Name of ...

  • 14.06.2007 – 09:27

    curasan AG: REVOIS® All-in-One Dental Implant System Registered in the U.S.

    ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. new product Kleinostheim (euro adhoc) - curasan AG, a German leader in regenerative medicine, has obtained FDA clearance for its REVOIS® All-in-One dental implant system, permitting the sale of the system in the U.S. This means that the system can be ...